Compare EB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EB | MYGN |
|---|---|---|
| Founded | 2003 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.9M | 481.6M |
| IPO Year | 2018 | 1996 |
| Metric | EB | MYGN |
|---|---|---|
| Price | $4.51 | $4.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | $5.00 | ★ $8.06 |
| AVG Volume (30 Days) | 998.4K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.62 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $326,134,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | $4.70 | $5.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.99 | 2.33 |
| 52 Week Low | $1.81 | $3.76 |
| 52 Week High | $4.48 | $11.44 |
| Indicator | EB | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 76.38 | 43.74 |
| Support Level | $4.43 | $3.93 |
| Resistance Level | N/A | $5.67 |
| Average True Range (ATR) | 0.02 | 0.39 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 95.45 | 44.41 |
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.